77 Year-Old Female Patient

Node: Negative

Size: 0.6 cm

Grade: 2

Case submitted by:
Rasa Buntinas — Cedar Rapids, IA, USA

Patient Details

Menopausal status:

Post-Menopausal

Tumor type:

Ductal

Tumor size:

0.6 cm

ER status (IHC):

Positive

PR status (IHC):

Negative

HER2/NEU status:

Negative

Ki-67 status:

N/A

Histologic grade:

2

Lymph node status:

Negative

General health:

ECOG 1

Treatment given:

Patient declined chemo

Other information

<p><b>Exploratory Subgroup Analysis</b> for TAILORx and NSABP B-20 indicate that Recurrence Score<sup>&reg;</sup> and age are the strongest predictors of chemotherapy benefit<sup class="referenceLink">1</sup>. The absolute reduction of distant recurrence from chemotherapy for patients >50 years and ≤50 years is shown here for RS groups: 11-15, 16-20, and 21-25 from TAILORx, and 0-10 and 26-100 from NSABP B-20<sup class="referenceLink">2</sup>.</p> <img src="/-/media/project/precisiononcology/oncotypeiq/case-studies/invasive-breast/reportanalysis.png?rev=09622a20277c45bbba231663e06267fb&amp;hash=365A2D8A987FF6830A7D3AC5B026937C" /> <p style="font-weight:bold;">Estimated Chemotherapy Benefit for Individual Recurrence Score Results</p> <p>Recurrence Score ranges shown reflect randomized patients in NSABP B-20 and TAILORx.</p> <img src="/-/media/project/precisiononcology/oncotypeiq/case-studies/invasive-breast/chemobenefit_b20tailorx.png?rev=09622a20277c45bbba231663e06267fb&amp;hash=CE30C7AFE4126071738A81830F43B88C" />

OncotypeDX® Patient Report
Download report
References and footnotes

1. Sparano et al. N Engl J Med. 2018.; ECOG and Genomic Health (data on file).

2. Paik et al. J Clin Oncol. 2006.; Sparano and Paik J Clin Oncol. 2008.

Disclaimer: These case studies are brought to you for educational purposes only and should not be interpreted as an endorsement of Exact Sciences or its services by the submitting physician. The information reflects the interpretive diagnostic opinions of the treating physicians and is not intended to represent a standard of care. The case studies describe real-life cases of patients who have been prescribed the Oncotype DX® test. They are not necessarily representative of all tested patients, and the result in any given case will vary. The examples are not necessarily representative of all of those who will use our clinical tests. Exact Sciences does not endorse any of the contributors featured on this site and takes no view as to the treatment decisions reported in these cases.